Author:
Haddad Natalie S.,Nguyen Doan C.,Kuruvilla Merin E.,Morrison-Porter Andrea,Anam Fabliha,Cashman Kevin S.,Ramonell Richard P.,Kyu Shuya,Saini Ankur Singh,Cabrera-Mora Monica,Derrico Andrew,Alter David,Roback John D.,Horwath Michael,O’Keefe James B.,Wu Henry M.,Ian Wong An-Kwok,Dretler Alexandra W.,Gripaldo Ria,Lane Andrea N.,Wu Hao,Lee Saeyun,Hernandez Mindy,Engineer Vanessa,Varghese John,Le Sang,Sanz Iñaki,Daiss John L.,Eun-Hyung Lee F.
Abstract
AbstractBackgroundSARS-CoV-2 has caused over 36,000,000 cases and 1,000,000 deaths globally. Comprehensive assessment of the multifaceted anti-viral antibody response is critical for diagnosis, differentiation of severe disease, and characterization of long-term immunity. Initial observations suggest that severe disease is associated with higher antibody levels and greater B cell/plasmablast responses. A multi-antigen immunoassay to define the complex serological landscape and clinical associations is essential.MethodsWe developed a multiplex immunoassay and evaluated serum/plasma from adults with RT-PCR-confirmed SARS-CoV-2 infections during acute illness (N=52) and convalescence (N=69); and pre-pandemic (N=106) and post-pandemic (N=137) healthy adults. We measured IgA, IgG, and/or IgM against SARS-CoV-2 Nucleocapsid (N), Spike domain 1 (S1), receptor binding domain (S1-RBD) and S1-N-terminal domain (S1-NTD).ResultsTo diagnose infection, the combined [IgA+IgG+IgM] or IgG for N, S1, and S1-RBD yielded AUC values −0.90 by ROC curves. From days 6-30 post-symptom onset, the levels of antigen-specific IgG, IgA or [IgA+IgG+IgM] were higher in patients with severe/critical compared to mild/moderate infections. Consistent with excessive concentrations of antibodies, a strong prozone effect was observed in sera from severe/critical patients. Notably, mild/moderate patients displayed a slower rise and lower peak in anti-N and anti-S1 IgG levels compared to severe/critical patients, but anti-RBD IgG and neutralization responses reached similar levels at 2-4 months.ConclusionThis SARS-CoV-2 multiplex immunoassay measures the magnitude, complexity and kinetics of the antibody response against multiple viral antigens. The IgG and combined-isotype SARS-CoV-2 multiplex assay is highly diagnostic of acute and convalescent disease and may prognosticate severity early in illness.One Sentence SummaryIn contrast to patients with moderate infections, those with severe COVID-19 develop prominent, early antibody responses to S1 and N proteins.
Publisher
Cold Spring Harbor Laboratory
Reference39 articles.
1. J. F. Chan et al., Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-polymerase chain reaction assay validated in vitro and with clinical specimens. Journal of clinical microbiology, (2020).
2. Serologic and molecular biologic methods for SARS-associated coronavirus infection, Taiwan;Emerg Infect Dis,2004
3. J. Zhao et al., Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, (2020).
4. R. C. Group et al., Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. The New England journal of medicine, (2020).